Previous 10 | Next 10 |
Shares of Mirati Therapeutics ( MRTX ) have risen by over 800% since my September 2017 article called the stock a Buy and noted it was poised to capitalize on the emerging theme of targeted oncology (much like prior picks in the space Loxo Oncology and Ignyta). A couple months later, I encou...
Preliminary data from an open-label Phase 1 clinical trial evaluating Amgen's (NASDAQ: AMGN ) KRAS G12C inhibitor AMG 510 in patients with solid tumors showed a positive effect. The data were presented at ASCO in Chicago. More news on: Amgen Inc., Mirati Therapeutics, Inc., Health...
Castor Maritime (NASDAQ: CTRM ) +112% on 1H results . More news on: Castor Maritime Inc., Attis Industries, Inc., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...
Gainers: Genocea Biosciences (NASDAQ: GNCA ) +45% . Mirati Therapeutics (NASDAQ: MRTX ) +34% . Cypress Semiconductor (NASDAQ: CY ) +25% . ARCA biopharma (NASDAQ: ABIO ) +23% . Centrus Energy (NYSEMKT: LEU ) +18% . Spirit MTA REIT (NYSE: SMTA ) +18% . El Paso Electric (NYSE: EE ...
Mirati Therapeutics ( MRTX +32.4% ) is up on over 40% higher volume in apparent response to Phase 1 data on Amgen's KRAS G12C inhibitor AMG 510 presented at ASCO in Chicago. More news on: Mirati Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais...
SAN DIEGO , May 30, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will present at the Jefferies Annual Global Healthcare Conference in New York on Thursday, June 6 th at 2:00 p.m. ET / 11:00 a.m. PT . Charles M. Bau...
Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor...
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...
Gainers: Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...